New prostate cancer drug tested in china: safety first
NCT ID NCT06136598
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 19 times
Summary
This early-stage study tested a new drug called MK-5684 in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal was to check the drug's safety and how the body processes it, not to prove it works. Participants took the drug and were monitored for side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital-Urology ( Site 0001)
Beijing, Beijing Municipality, 100034, China
-
Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)
Guangzhou, Guangdong, 510700, China
-
Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.